Monopar Therapeutics - Common Stock, par value $0.001 per share (MNPR)
CUSIP: 61023L207
Q3 2024 13F Holders as of 30 Sep 2024
- Type / Class
- Equity / Common Stock, par value $0.001 per share
- Shares outstanding
- 6,743,758
- Total 13F shares
- 15,707
- Share change
- +15,707
- Total reported value
- $105,865
- Price per share
- $6.74
- Number of holders
- 6
- Value change
- +$105,865
- Number of buys
- 6
Quarterly Holders Quick Answers
What is CUSIP 61023L207?
CUSIP 61023L207 identifies MNPR - Monopar Therapeutics - Common Stock, par value $0.001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Related Filing Research
- Latest 13F filings for newly reported positions.
- Latest Schedule 13D/13G reports for ownership changes outside 13F cadence.
- Latest 10-Q/10-K reports for financial context tied to this issuer.
- Recent insider transactions for executive and insider activity.
- SEC investors directory and top value investors for manager drilldown.
- Back to full security ownership history.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
- Newer quarter: Q4 2024
Recent filing periods for CUSIP 61023L207:
Top shareholders of MNPR - Monopar Therapeutics - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
—
class O/S missing
|
194,298
|
$145,335 | — | 30 Jun 2024 | |
| Michael J. Brown |
3/4/5
|
Director |
—
class O/S missing
|
402,530
|
$136,941 | — | 31 Dec 2023 | |
| Andrew Paul Mazar |
3/4/5
|
Chief Scientific Officer, Director |
—
mixed-class rows
|
277,584
mixed-class rows
|
$94,434 | — | 31 Mar 2022 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
—
class O/S missing
|
60,036
|
$44,906 | — | 30 Jun 2024 | |
| TWO SIGMA SECURITIES, LLC |
13F
|
Company |
—
class O/S missing
|
47,058
|
$34,357 | — | 30 Jun 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
—
class O/S missing
|
45,167
|
$32,976 | — | 30 Jun 2024 | |
| GERBER, LLC |
13F
|
Company |
—
class O/S missing
|
28,005
|
$20,446 | — | 30 Jun 2024 | |
| Virtu Financial LLC |
13F
|
Company |
—
class O/S missing
|
18,840
|
$14,000 | — | 30 Jun 2024 | |
| Rappaport Reiches Capital Management, LLC |
13F
|
Company |
—
class O/S missing
|
10,695
|
$7,808 | — | 30 Jun 2024 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
—
class O/S missing
|
7,922
|
$5,783 | — | 30 Jun 2024 | |
| NewEdge Advisors, LLC |
13F
|
Company |
—
class O/S missing
|
3,000
|
$2,190 | — | 30 Jun 2024 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
—
class O/S missing
|
2,500
|
$1,825 | — | 30 Jun 2024 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
—
class O/S missing
|
561
|
$410 | — | 30 Jun 2024 | |
| Federation Des Caisses Desjardins du Quebec |
13F
|
Individual |
—
class O/S missing
|
80
|
$58 | — | 30 Jun 2024 | |
| Jose Octavio Pinto Costa Filho |
3/4/5
|
Chief Medical Officer |
—
class O/S missing
|
91,500
|
— | — | 12 Jul 2021 |
Institutional Holders of Monopar Therapeutics - Common Stock, par value $0.001 per share (MNPR) as of Q3 2024
As of 30 Sep 2024,
Monopar Therapeutics - Common Stock, par value $0.001 per share (MNPR) was held by
6 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
15,707 shares.
The largest 6 holders included
GEODE CAPITAL MANAGEMENT, LLC, NewEdge Advisors, LLC, UBS Group AG, WELLS FARGO & COMPANY/MN, Federation des caisses Desjardins du Quebec, and BANK OF AMERICA CORP /DE/.
This page lists
6
institutional shareholders reporting positions in this security
for the Q3 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q3 2024 vs Q4 2025 Across Filers
Q4 2025 holders
73
Q3 2024 holders
6
Holder diff
-67
| Investor | Q4 2025 Shares | Q3 2024 Shares | Share Diff | Share Chg % | Q4 2025 Value $ | Q3 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.